Agenus Inc (AGEN)

$11.09

+0.6

(+5.72%)▲

Market is closed - opens 7 PM, 14 May 2024

Performance

  • $10.45
    $11.26
    $11.09
    downward going graph

    5.74%

    Downside

    Day's Volatility :7.16%

    Upside

    1.51%

    downward going graph
  • $4.78
    $42.60
    $11.09
    downward going graph

    56.9%

    Downside

    52 Weeks Volatility :88.78%

    Upside

    73.97%

    downward going graph

Returns

PeriodAgenus Inc
3 Months
-31.0%
6 Months
-16.48%
1 Year
-65.49%
3 Years
-82.69%

Highlights

Market Capitalization
246.1M
Book Value
- $9.6
Earnings Per Share (EPS)
-13.8
PEG Ratio
0.0
Wall Street Target Price
74.25
Profit Margin
-148.31%
Operating Margin TTM
-117.42%
Return On Assets TTM
-25.81%
Return On Equity TTM
-1278.83%
Revenue TTM
161.4M
Revenue Per Share TTM
8.49
Quarterly Revenue Growth YOY
22.3%
Gross Profit TTM
82.6M
EBITDA
-123.8M
Diluted Eps TTM
-13.8
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-8.84
EPS Estimate Next Year
-9.72
EPS Estimate Current Quarter
-3.22
EPS Estimate Next Quarter
-3.75

Analyst Recommendation

Buy
    90%Buy
    9%Hold
    0
    0%Sell
Based on 11 Wall street analysts offering stock ratings for Agenus Inc(by analysts ranked 0 to 5 stars)
Based on 11 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
10
11
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 569.52%

Current $11.09
Target $74.25

Company Financials

FY18Y/Y Change
Revenue
36.8M
↓ 14.21%
Net Income
-159.7M
↑ 32.31%
Net Profit Margin
-434.14%
↓ 152.66%
FY19Y/Y Change
Revenue
150.0M
↑ 307.92%
Net Income
-149.1M
↓ 6.61%
Net Profit Margin
-99.39%
↑ 334.75%
FY20Y/Y Change
Revenue
88.2M
↓ 41.24%
Net Income
-240.1M
↑ 61.02%
Net Profit Margin
-272.35%
↓ 172.96%
FY21Y/Y Change
Revenue
295.7M
↑ 235.34%
Net Income
-94.7M
↓ 60.57%
Net Profit Margin
-32.03%
↑ 240.32%
FY22Y/Y Change
Revenue
98.0M
↓ 66.85%
Net Income
-271.5M
↑ 186.72%
Net Profit Margin
-276.99%
↓ 244.96%
FY23Y/Y Change
Revenue
156.3M
↑ 59.47%
Net Income
-245.8M
↓ 9.49%
Net Profit Margin
-157.22%
↑ 119.77%
Q4 FY22Q/Q Change
Revenue
28.4M
↑ 24.65%
Net Income
-97.4M
↑ 31.13%
Net Profit Margin
-343.12%
↓ 16.94%
Q1 FY23Q/Q Change
Revenue
22.9M
↓ 19.32%
Net Income
-67.8M
↓ 30.34%
Net Profit Margin
-296.25%
↑ 46.87%
Q2 FY23Q/Q Change
Revenue
25.3M
↑ 10.45%
Net Income
-73.4M
↑ 8.23%
Net Profit Margin
-290.28%
↑ 5.97%
Q3 FY23Q/Q Change
Revenue
24.3M
↓ 3.88%
Net Income
-62.2M
↓ 15.29%
Net Profit Margin
-255.82%
↑ 34.46%
Q4 FY23Q/Q Change
Revenue
83.8M
↑ 244.66%
Net Income
-46.3M
↓ 25.58%
Net Profit Margin
-55.24%
↑ 200.58%
Q1 FY24Q/Q Change
Revenue
28.0M
↓ 66.58%
Net Income
-61.9M
↑ 33.81%
Net Profit Margin
-221.17%
↓ 165.93%
FY18Y/Y Change
Total Assets
136.4M
↓ 1.45%
Total Liabilities
310.9M
↑ 45.15%
FY19Y/Y Change
Total Assets
155.3M
↑ 13.88%
Total Liabilities
386.7M
↑ 24.35%
FY20Y/Y Change
Total Assets
214.5M
↑ 38.1%
Total Liabilities
426.0M
↑ 10.17%
FY21Y/Y Change
Total Assets
466.0M
↑ 117.22%
Total Liabilities
418.0M
↓ 1.87%
FY22Y/Y Change
Total Assets
413.6M
↓ 11.25%
Total Liabilities
468.5M
↑ 12.06%
FY23Y/Y Change
Total Assets
313.9M
↓ 24.09%
Total Liabilities
462.3M
↓ 1.32%
Q4 FY22Q/Q Change
Total Assets
413.6M
↓ 3.6%
Total Liabilities
468.5M
↑ 6.26%
Q1 FY23Q/Q Change
Total Assets
412.9M
↓ 0.17%
Total Liabilities
466.0M
↓ 0.53%
Q2 FY23Q/Q Change
Total Assets
383.6M
↓ 7.09%
Total Liabilities
460.4M
↓ 1.2%
Q3 FY23Q/Q Change
Total Assets
335.5M
↓ 12.54%
Total Liabilities
450.8M
↓ 2.08%
Q4 FY23Q/Q Change
Total Assets
313.9M
↓ 6.43%
Total Liabilities
462.3M
↑ 2.56%
Q1 FY24Q/Q Change
Total Assets
256.6M
↓ 18.27%
Total Liabilities
318.9M
↓ 31.02%
FY18Y/Y Change
Operating Cash Flow
-131.1M
↑ 39.13%
Investing Cash Flow
-3.6M
↓ 273.98%
Financing Cash Flow
128.3M
↑ 59.28%
FY19Y/Y Change
Operating Cash Flow
-18.7M
↓ 85.75%
Investing Cash Flow
-4.7M
↑ 29.69%
Financing Cash Flow
31.3M
↓ 75.58%
FY20Y/Y Change
Operating Cash Flow
-139.1M
↑ 644.55%
Investing Cash Flow
-4.4M
↓ 4.64%
Financing Cash Flow
183.9M
↑ 486.96%
FY21Y/Y Change
Operating Cash Flow
10.1M
↓ 107.29%
Investing Cash Flow
-43.2M
↑ 871.63%
Financing Cash Flow
225.3M
↑ 22.52%
FY22Y/Y Change
Operating Cash Flow
-175.4M
↓ 1828.66%
Investing Cash Flow
-33.6M
↓ 22.11%
Financing Cash Flow
95.8M
↓ 57.46%
Q4 FY22Q/Q Change
Operating Cash Flow
-47.3M
↑ 47.05%
Investing Cash Flow
-6.4M
↓ 59.18%
Financing Cash Flow
23.8M
↓ 15.77%
Q1 FY23Q/Q Change
Operating Cash Flow
-58.5M
↑ 23.63%
Investing Cash Flow
-11.5M
↑ 79.99%
Financing Cash Flow
56.3M
↑ 136.61%
Q2 FY23Q/Q Change
Operating Cash Flow
-44.5M
↓ 23.99%
Investing Cash Flow
517.0K
↓ 104.5%
Financing Cash Flow
38.3M
↓ 31.98%

Technicals Summary

Sell

Neutral

Buy

Agenus Inc is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Agenus Inc
Agenus Inc
61.38%
-16.48%
-65.49%
-82.69%
-82.34%
Moderna, Inc.
Moderna, Inc.
12.95%
67.08%
-9.94%
-21.73%
380.19%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
8.37%
22.23%
29.67%
88.29%
219.12%
Novo Nordisk A/s
Novo Nordisk A/s
3.65%
27.43%
51.59%
225.57%
442.2%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
8.2%
14.28%
23.31%
94.75%
157.88%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Agenus Inc
Agenus Inc
8.2
NA
0.0
-8.84
-12.79
-0.26
NA
-9.6
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-6.67
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
28.57
28.57
1.46
44.24
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
44.83
44.83
2.4
3.4
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
27.17
27.17
0.53
16.94
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Agenus Inc
Agenus Inc
Buy
$246.1M
-82.34%
8.2
-148.31%
Moderna, Inc.
Moderna, Inc.
Buy
$47.0B
380.19%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$106.7B
219.12%
28.57
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$573.2B
442.2%
44.83
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$108.1B
157.88%
27.17
39.46%

Institutional Holdings

  • BlackRock Inc

    7.70%

  • Deep Track Capital, LP

    7.57%

  • Vanguard Group Inc

    7.23%

  • Sofinnova Ventures

    3.74%

  • Artal Group S A

    3.73%

  • State Street Corporation

    2.07%

Company Information

agenus is an immunology company discovering and developing novel checkpoint modulators, vaccines and adjuvants to treat cancer and other diseases. we are a dedicated group of scientists, researchers, biotechnologists, physicians, and businesspeople working together toward one goal: to discover and develop therapies that can unleash the innate power of the body’s immune system to treat and potentially cure hard-to-treat cancers and other diseases. our product candidates are designed to work by educating and activating the body’s immune system for a precise and potent attack on cancer. our strategy is to help unlock the potential of one of the most exciting breakthrough areas in cancer treatment in decades, and to develop single agent and combination immune-oncology therapies that can help save lives. our approaches are driven by three platform technologies, including: • our antibody platforms, including our proprietary retrocyte display™ and secant® technologies, and our antibody

Organization
Agenus Inc
Employees
389
CEO
Dr. Garo H. Armen Ph.D.
Industry
Health Technology

Discover More

FAQs